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induction chemotherapy (cyclophosphamide, daunorubicin, vin-
cristine and MTX i.t.). After induction all patients had to receive a
HAM consolidation course (HD-AraC 3 g/m2 every 12 hours, days
1-4; mitoxantrone 10 mg/m2, days 5-7 and MTX i.t.). Patients in
CR received two courses of MA consolidation (MTX 1.5 g/m2 day
1 and l-asparaginase 104 IU/m2 day 2), and then underwent allo-
SCT or patients without a donor were randomized either to re-
ceive autologous stem cells from peripheral blood or high main-
tenance therapy. The median follow-up was 4.9 years. Between
1998 and 2003, a total of 325 pts entered the study. The median
age was 32 yrs range 15-72 yrs. In 248 (76%) patients CR1 was
reached and 227 of them were HLA typed; 100 had an identical
sibling donor and 127 had no sibling donor. Allo-SCT was per-
formed in 69 (69%) pts and auto-SCT or high maintenance ther-
apy in 58 (46%). The 5-year DFS of pts with a donor vs pts without
a donor was 41.8% vs. 35.5% , P  .40, hazard ratio 0.86, 95% CI
0.61-1.22). The relapse incidence was signiﬁcantly lower (37.3%
vs. 58.8% P  .004) and treatment related mortality (TRM) was
signiﬁcantly higher (20.9% vs. 5.7%, P  .0005) in the donor
group compared to the no donor group. Five-year survival in pts
with and without the donor was 43.0% and 36.9% respectively. For
pts50 years of age 199 of them were HLA-typed; 91 had a donor
and 108 had no sibling donor. The 5-yr DFS rate in the donor vs
no donor group was 42.2% vs. 36.2%, P  .36, hazard ratio 0.84
95% CI 0.58-1.22). Relapse rate was signiﬁcantly lower and TRM
was signiﬁcantly higher in the donor versus no donor group.
Five-year survival for patients with and without a donor was 43.9%
and 37.4% respectively (P  .58), hazard ratio 0.90 (95% CI
0.61-1.32). In conclusion, in the EORTC ALL-4 trial, the inten-
tion to treat analysis shows that DFS and survival rate for al-
lografted pts younger than 50 years of age were not signiﬁcantly
different compared to those receiving auto-SCT or high mainte-
nance. High TRM (20%) remains the main problem of allograft-
ing.
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Background: High dose (HD) cyclophosphamide (CY, 200 mg/
kg) plus ATG seems to be accepted as standard conditioning
regimen in HLA-matched sibling stem cell transplantation (SCT)
for severe aplastic anemia (SAA). However, HD CY causes serious
cardiac toxicity in some cases which may lead to death within a few
weeks. To avoid HD CY-associated cardiac toxicity we underwent
HLA-matched sibling SCT using ATG, reduced CY to half dose
with incorporation of ﬂudarabine. Methods: Between March 2002
and August 2005, consecutive twenty-six patients with adult SAA
(six patients were AA/PNH syndrome) received matched sibling
SCT. The median age of patients was 41 (21-52) and median
interval between Dx and SCT was 30 months (1-352). The median
number of transfusions prior to SCT was 34 units (4-680). Ten
patients (38%) had a history of IST before SCT. The conditioning
regimen consisted of ﬂudarabine (30 mg/m2/day, 6 days), cyclo-
phosphamide (50 mg/kg/day, 2 days) and ATG (2.5 mg/kg/day, 4
days, IMTIX-SangStat). Stem cell sources were BM plus CD34-
selected PBSC (n 9), BM (n 14), or PBSC (n 3). All patients
received of cyclosporine and methotrexate as GVHD prophylaxis.
Results: The median dose of CD34 cells infused was 3.6 
106/kg (1.2-11.9). All patients achieved successful sustained en-
graftment, and the median time for ANC and platelet to reach
0.5  109/L and 20  109/L was 12 (6-16) and 18 (10-23) days,
respectively. None of the patients developed cardiac toxicity or
regimen-related toxicities. One patient developed delayed graft
failure, but achieved successful engraftment after second SCT
using TNI  ATG. The incidence of acute GVHD (more than
grade II) was 8% (n 2) and none developed chronic GVHD. The
incidence of CMV infection requiring preemptive treatment was
38% (n  10). Only one patient died of hepatic failure due to
reactivation of chronic hepatitis C with hepatic GVHD posttrans-
plant 3 months. PNH clone measured by ﬂow cytometry disap-
peared posttransplant in 6 PNH patients. With median follow up
of 12 months (2-41), the estimated probability of survival at 2 years
was 96%. Conclusions: These data demonstrate that the condi-
tioning regimen used in this study is feasible for patients with SAA
who receive matched sibling SCT. Of note, the observations of
successful engraftment as well as lesser acute GVHD and no
chronic GVHD suggest that a ﬂudarabine-based regimen has more
potent immunomodulatory activity.
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RESPIRATORY VIRUS INFECTION AMONG HEMATOPOIETIC CELL
TRANSPLANTATION (HCT) RECIPIENTS: QUANTITATIVE VIRAL LOAD
IN SYMPTOMATIC AND ASYMPTOMATIC INFECTIONS
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Background: Inﬂuenza (ﬂu), respiratory syncytial virus (RSV), and
parainﬂuenza virus (PIV) may cause serious respiratory disease fol-
lowing HCT, with infection rates of 2-10%. The extent of infection
and disease due to human metapneumovirus (MPV) is largely un-
known. We assessed viral infectious episodes after HCT using con-
ventional and quantitative molecular detection. Methods: Weekly
symptom surveys, nasal washes and throat swabs were collected from
HCT recipients for 100 days post-HCT between Jan. 2001-June
2004. Samples were tested by culture and DFA for RSV, PIV and Flu,
and by RT-PCR for RSV, PIV, MPV, and ﬂu (detection limit 1100
copies/ml). Longitudinal analysis was performed for patients with5
serial samples or a positive test or death. Results:Of 119 patients, 29
had 31 (26%) separate infectious episodes due to RSV (5), PIV (16),
MPV (6), ﬂu (3), RSV and ﬂu (1). Median time to viral detection was
48 (range 3-96) days after HCT; median duration of viral shedding
was 14 (range 5-42) days in 19 evaluable episodes. Six patients with
PIV remained asymptomatic at the time of positivity, conventional
testing was negative in 5. No asymptomatic shedding of RSV, MPV
or ﬂu was found. PCR testing nearly doubled ﬁrst identiﬁcation of
RSV and PIV infectious episodes: 11 were detected by PCR plus
conventional methods (in 2 patients, PCR detection preceded con-
ventional methods) and 9 were detected by PCR alone. Median virus
copy number in samples from asymptomatic weeks (2.3 104 copies/
ml) differed from samples from symptomatic weeks (8.6 105 copies/
ml; P value .004). Similarly, viral load in samples from patients with 0
or 1 symptoms (2.4  104 copies/ml) was signiﬁcantly lower com-
pared with patients that reported 	1 symptom (1.8  106; P value
.001). PIV was the only virus that showed a lower viral load in patients
with 0 or 1 symptoms compared with 	1 (P value .04). Conclusion:
Both symptomatic and asymptomatic viral shedding among allogeneic
HCT recipients were detectable using virus-speciﬁc molecular test-
ing. Utilization of PCR viral detection methods increased yield of
detectable episodes. PIV infections were more likely to be transiently
asymptomatic than RSV, MPV, or ﬂu. Asymptomatic shedding of
PIV provides a possible explanation of why infection control pro-
grams emphasizing symptoms are highly effective against RSV but
often not versus other viruses such as PIV. These data may guide
implementation of more effective diagnosis and infection control
strategies.
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FLUDARABINE, 400 cGy TOTAL BODY IRRADIATION AND LOW-DOSE
ANTITHYMOCYTE GLOBULIN
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